Eli Lilly (LLY), Boehringer Ingelheim Note Presentation of Strong Jardiance Data in Cardiovascular Death Reduction for T2D Patients
Tweet Send to a Friend
New data presented today at the American Heart Association Scientific Sessions 2016 showed that Jardiance (empagliflozin) tablets consistently reduced the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
